A Consecutive Priming-boosting Vaccination of Mice with Simian Immunodeficiency Virus (SIV) Gag/pol DNA and Recombinant Vaccinia Virus Strain DIs Elicits Effective Anti-SIV Immunity

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2004 Aug 28

PMID 15331719

Citations 12

Authors

Kenji Someya

Ke-Qin Xin

Kazuhiro Matsuo

Kenji Okuda

Naoki Yamamoto

Mitsuo Honda

Affiliations

Soon will be listed here.

Abstract

To evaluate immunity induced by a novel DNA prime-boost regimen, we constructed a DNA plasmid encoding the gag and pol genes from simian immunodeficiency virus (SIV) (SIVgag/pol DNA), in addition to a replication-deficient vaccinia virus strain DIs recombinant expressing SIV gag and pol genes (rDIsSIVgag/pol). In mice, priming with SIVgag/pol DNA, followed by rDIsSIVgag/pol induced an SIV-specific lymphoproliferative response that was mediated by a CD4+-T-lymphocyte subset. Immunization with either vaccine alone was insufficient to induce high levels of proliferation or Th1 responses in the animals. The prime-boost regimen also induced SIV Gag-specific cellular responses based on gamma interferon secretion, as well as cytotoxic-T-lymphocyte responses. Thus, the regimen of DNA priming and recombinant DIs boosting induced Th1-type cell-mediated immunity, which was associated with resistance to viral challenge with wild-type vaccinia virus expressing SIVgag/pol, suggesting that this new regimen may hold promise as a safe and effective vaccine against human immunodeficiency virus type 1.

Citing Articles

Biodistribution and immunity of adenovirus 5/35 and modified vaccinia Ankara vector vaccines against human immunodeficiency virus 1 clade C.

Shimada M, Wang H, Ichino M, Ura T, Mizuki N, Okuda K Gene Ther. 2022; 29(10-11):636-642.

PMID: 34987192 DOI: 10.1038/s41434-021-00308-z.

HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.

Jongwe T, Chapman R, Douglass N, Chetty S, Chege G, Williamson A PLoS One. 2016; 11(7):e0159141.

PMID: 27427967 PMC: 4948879. DOI: 10.1371/journal.pone.0159141.

The evolution of poxvirus vaccines.

Sanchez-Sampedro L, Perdiguero B, Mejias-Perez E, Garcia-Arriaza J, Di Pilato M, Esteban M Viruses. 2015; 7(4):1726-803.

PMID: 25853483 PMC: 4411676. DOI: 10.3390/v7041726.

Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control.

Matsuo K, Yasutomi Y Tuberc Res Treat. 2012; 2011:574591.

PMID: 22567267 PMC: 3335490. DOI: 10.1155/2011/574591.

Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy.

Shimada M, Wang H, Kondo A, Xu X, Yoshida A, Shinoda K Gene Ther. 2008; 16(2):218-28.

PMID: 18923453 PMC: 7372711. DOI: 10.1038/gt.2008.152.

References

Putkonen P, Leandersson A, Schwartz S, Thorstensson R, Okuda K, Wahren B . Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts. Virology. 1998; 250(2):293-301. DOI: 10.1006/viro.1998.9379. View

Pontesilli O, Klein M, Pakker N, de Wolf F, Schuitemaker H, Miedema F . Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. J Infect Dis. 1998; 178(4):1008-18. DOI: 10.1086/515659. View

Chakrabarti B, Kong W, Yang Z, Friborg J, Ling X, King S . Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol. 2002; 76(11):5357-68. PMC: 137015. DOI: 10.1128/jvi.76.11.5357-5368.2002. View

Baig J, Levy D, McKay P, Schmitz J, Santra S, Subbramanian R . Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. J Virol. 2002; 76(22):11484-90. PMC: 136762. DOI: 10.1128/jvi.76.22.11484-11490.2002. View

Qiu J, Nayak R, Tullis G, Pintel D . Characterization of the transcription profile of adeno-associated virus type 5 reveals a number of unique features compared to previously characterized adeno-associated viruses. J Virol. 2002; 76(24):12435-47. PMC: 136721. DOI: 10.1128/jvi.76.24.12435-12447.2002. View

Ishii K, Ueda Y, Matsuo K, Matsuura Y, Kitamura T, Kato K . Structural analysis of vaccinia virus DIs strain: application as a new replication-deficient viral vector. Virology. 2002; 302(2):433-44. DOI: 10.1006/viro.2002.1622. View

Ohga S, Nomura A, Takada H, Hara T . Immunological aspects of Epstein-Barr virus infection. Crit Rev Oncol Hematol. 2002; 44(3):203-15. DOI: 10.1016/s1040-8428(02)00112-9. View

Hukkanen V, Broberg E, Salmi A, Eralinna J . Cytokines in experimental herpes simplex virus infection. Int Rev Immunol. 2002; 21(4-5):355-71. DOI: 10.1080/08830180213276. View

Sakaue G, Hiroi T, Nakagawa Y, Someya K, Iwatani K, Sawa Y . HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J Immunol. 2002; 170(1):495-502. DOI: 10.4049/jimmunol.170.1.495. View

10.

Mwau M, McMichael A . A review of vaccines for HIV prevention. J Gene Med. 2003; 5(1):3-10. DOI: 10.1002/jgm.343. View

11.

Otten G, Chen M, Doe B, Zur Megede J, Barnett S, Ulmer J . Quantitative assessment of antigen-specific CD8+ T cells in the mouse: application to vaccine research. Immunol Lett. 2003; 85(2):215-22. DOI: 10.1016/s0165-2478(02)00237-7. View

12.

Hofmann-Lehmann R, Vlasak J, Williams A, Chenine A, McClure H, Anderson D . Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS. 2003; 17(2):157-66. DOI: 10.1097/00002030-200301240-00004. View

13.

Katz A . HIV update. J Obstet Gynecol Neonatal Nurs. 2003; 32(1):86. View

14.

Pisani E, Lazzari S, Walker N, Schwartlander B . HIV surveillance: a global perspective. J Acquir Immune Defic Syndr. 2003; 32 Suppl 1:S3-11. DOI: 10.1097/00126334-200302011-00002. View

15.

Moss R, Webb E, Giermakowska W, JENSEN F, Savary J, Wallace M . HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant. J Acquir Immune Defic Syndr. 2000; 24(3):264-9. DOI: 10.1097/00126334-200007010-00012. View

16.

Hel Z, Venzon D, Poudyal M, Tsai W, Giuliani L, Woodward R . Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med. 2000; 6(10):1140-6. DOI: 10.1038/80481. View

17.

Rico M, Quiroga J, Subira D, Castanon S, Esteban J, Pardo M . Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha. Hepatology. 2000; 33(1):295-300. DOI: 10.1053/jhep.2001.21147. View

18.

Amara R, Villinger F, Altman J, Lydy S, ONeil S, Staprans S . Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 2001; 292(5514):69-74. DOI: 10.1126/science.1058915. View

19.

McMichael A, Rowland-Jones S . Cellular immune responses to HIV. Nature. 2001; 410(6831):980-7. DOI: 10.1038/35073658. View

20.

Huang Y, Kong W, Nabel G . Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J Virol. 2001; 75(10):4947-51. PMC: 114253. DOI: 10.1128/JVI.75.10.4947-4951.2001. View